The Striatal DNA Damage and Neurodegenerations by Li, Huifangjie & Xu, Jinbin
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










Reactive oxygen species (ROS) are produced during normal metabolic reac-
tions in living cells. ROS causes oxidative damage to many types of biomolecules. 
An age-related increase in oxidative damage to DNA and RNA has been described 
in the human neurons, which play a vital role in the progression of age-associated 
neurodegeneration. As dopamine metabolism is believed to be the primary 
source of ROS, oxidative insults correlate with dopamine levels in the striatum 
during the progression of neurodegenerative diseases. Parallel changes in dopa-
mine concentrations and vesicular monoamine transporter 2 (VMAT2) binding 
densities in the striatum were observed. Besides Fenton oxidation taking place, 
the packing of cytosolic dopamine into synaptic vesicles by VMAT2 inhibits its 
autoxidation and subsequent decay of dopaminergic neurons. The female bias 
in the DNA damage in the late-stage Parkinson disease (PD) patients suggests 
that the sex-determining region of the Y chromosome (SRY) genes are criti-
cally involved. ROS are involved in regulating the rate of the aging procession in 
healthy cohorts and an increased life span of patients with neurodegenerative 
diseases via stimulation of protective stress responses. Moreover, the DNA repair 
pathway’s mechanism, as genetic modifiers determine the age at onset through a 
ROS-inducing mutation.
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1. Introduction
Oxidative damage can come from harmful environments such as chemical 
agents and ionizing radiation, but the major oxidative damage is also caused by 
internally sourced reactive oxygen species (ROS) generated from the natural 
metabolic processes in living cells. As the brain has a relatively higher oxygen 
demand and lower levels of antioxidants than other organs, ROS generates 
mainly DNA damage in the brain [1]. Numerous studies show that the accumula-
tion of neuronal DNA damage contributes to the progress of aging [2]. DNA 
bases frequently undergo lesions through modification by alkylation, oxidation, 
and deamination [3]. To protect against these destructive adducts, cells have 
developed an antioxidant defense system to be expressed by enzymes involved in 
base excision repair (BER). The imbalance between clearance and generation of 
ROS plays a critical role in disease pathogenesis. Except for healthy aging, insuf-
ficient DNA repair has been tightly associated with neurodegenerative disorders 
such as Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic 
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lateral sclerosis (ALS) [4–9]. The elevated DNA strand breaks and the decreased 
DNA double-strand breaks (DSBs) repair proteins have been described in AD 
brains.
Additionally, the increase in β-amyloid (Aβ) and neurofibrillary tangles 
(NFTs) is closely linked to decreased oxidative damage—an early event in 
AD that decreases with disease progression [10]. What is more, the lesions to 
mitochondrial, a major source of ROS, have been reported in the PD cases, and 
mitochondrial dysfunctions have been associated with the disease pathophysiol-
ogy. Historically, the first investigation involving mitochondria in PD relates to 
the observation that the presence of an impairment of complex I in the different 
forms of PD and Parkinsonism [11]. Dementia with Lewy bodies (DLB), Parkinson 
disease dementia (PDD), and PD have been aggregated conceptually as Lewy body 
disease (LBD) [12].
Striatal dopaminergic dysfunction probably is involved in both AD and LBD, 
while degeneration of nigrostriatal dopaminergic neurons is the classic pathology 
of PD; striatal dopaminergic dysfunction may also promote the motor manifesta-
tions of AD. The striatum consists of several subregions—caudate and putamen. 
The caudate nucleus is essential in many behaviors, including procedural learning 
and working memory; the dorsal posterior putamen receives its primary input 
from the motor and sensorimotor cortices and regulates the motor circuits [13–15]. 
Dopamine generates hydroxyl radical (•OH) through Fenton reactions in the 
presence of iron, which is believed to be responsible for the oxidative damage to 
lipids, proteins, and DNA in living cells and dopaminergic neurons [16]. Besides, 
as a chelator, dopamine can form different complexes with Fe(II) and Fe(III), 
decreasing catalytic productions of ROS [17]. Dopamine compartmentalization has 
been described by the vesicular monoamine transporter 2 (VMAT2)—correlates 
with dopaminergic neurons’ vulnerability in Parkinsonism neurodegeneration [18]. 
There are close interactions among oxidative damage and dopamine concentra-
tion, and the antioxidant role of VMAT2 should be given more attention. Oxidative 
stress induced by genetics has been linked to the Y-chromosome gene products that 
modulate dopamine biosynthesis and motor function [19]. Further, DNA dam-
age is associated with acceleration of the rate of aging, causing a variety of early 
symptoms such as gray hair, kidney disease, cataracts, osteoporosis, and neuronal 
atrophy [20]—factors which determine the health or disease people’s life span and 
age at the onset of diseases.
Therefore, it is clear that there is an appreciable need for a better understanding 
of the correlations between oxidative damage and neurodegenerations. In this chap-
ter, the striatal DNA damage was first focused, and its brain region concentrations 
in neurodegenerative diseases will be discussed with parallel changes of dopamine 
levels and VMAT2 densities. Moreover, original data on the association among 
striatal DNA damages, sex, life span, and the age of onset of diseases in neurode-
generative patients will be presented.
2.  Oxidative damage of DNA in the striatum from patients with 
neurodegenerative diseases
It is widely recognized that 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) 
and 8-oxo-7,8-dihydroguanosine (8-oxo-G) may act as biomarkers of oxidative 
damage to DNA and RNA, respectively [1]. Studies by Li et al. have reported the 
levels of DNA adducts in the caudate and putamen of the disease groups and 
age-matched controls [21]. Compared to controls, remarkable reductions in DNA 
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oxidation adducts were observed in the caudate of PD and DLB brains, including 
males and females. However, in the caudate of AD brains, these levels were elevated. 
This finding was especially pronounced for male AD patients, as adduct levels were 
36% elevated compared to controls (Figure 1). The concentrations of 8-oxo-dG in 
the putamen of the disease groups were similar to the controls. Comparing between 
caudate and putamen, there were impressive elevations in adduct levels in the 
caudate, especially for the AD brains. These data indicate that the caudate is more 
vulnerable to DNA damage than the putamen in advanced AD patients.
RNA bases are more exposed and vulnerable to oxidative damage than DNA as 
they are not protected by hydrogen bonding and specific proteins. RNA oxidation 
has been described as a “steady-state” marker of oxidative lesions [22]; however, 
DNA oxidation has been believed to be a historical marker of oxidative damage dur-
ing disease pathogenesis and aging progression [23]. Increased 8-OHdG levels have 
been documented in PD patients [24–26], but as shown in Figure 1, a noticeable 
reduction of DNA oxidation adducts in the caudate was observed in the late-stage 
LBD brains. It was not unique; the urinary concentration of 8-OHdG in the MFB 
6-hydroxydopamine lesion model started to elevate at day 3 with a significant 
increase to day 7 and gradually back to baseline at day 42 [27]. The increased 8-oxo-
dG levels in the caudate of AD brains connected with the increase in dopamine 
levels of the same cases. These phenomena are most likely due to the Fenton reac-
tions taking place—in response to dopamine release and dopamine compartmental-
ization by VMAT2 [28].
Figure 1. 
8-oxo-dG levels in the caudate and putamen of patients with diseases (PD: n = 10, PDD: n = 7, DLB: n = 10, 
and AD: n = 26) and age-matched controls (n = 10). Values shown are means ± SEM as the concentration of 
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) (pg) per total DNA (μg). (a) Female and (b) male.
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3.  Interactions between oxidative damage and dopamine in the striatum 
of patients with neurodegenerative diseases
There are three biologically critical free radicals in our body, O2
•−, •OH, and 
NO•, mainly produced through Fenton oxidative reaction. Fenton reactions are 
catalytic oxidation reactions starting with transition metal ions, either iron or 
copper, and yielding both the hydroxyl radical (•OH) and higher oxidation states 
of the iron [29].
 + + -+ ® + +•Fe H O Fe OH OH2 32 2  (1)
 + + ++ ® + +•Fe H O Fe OOH H3 22 2  (2)
The relatively large amount of hydroxyl radical attacks adjacent to mitochondrial 
DNA strands and cytoplasmic RNA single-strands consequently produce an amount 
of oxidative adducts [29]. It is also critical to note that dopamine is metabolized 
enzymatically to produce a mass of H2O2 and, ultimately, dihydroxyphenylacetate, 
conversely promoting the dopaminergic exposure neurons to oxidative lesions. Put 
it another way, dopamine and related catechol are vulnerable molecules that can 
oxidize in the presence of transition metals to yield O2
−, playing an essential role in 
nucleic oxidation as a major ROS source. O2
−, a product of catechol autoxidation, 
can reversely oxidize catechol [30]. Either spontaneously or enzymatically, O2
− can 
yield H2O2 and then •OH in the presence of transition metals [11]. The imbalance 
between clearance and generation of ROS promotes progressive dysfunction or 
increased death of dopaminergic neurons. Also, dopamine affects as a good metal 
chelator and electron donor and is capable of capturing iron and manganese [17]. 
Fe3+ has been reported as a catalyst for autoxidation of dopamine via the following 
mechanism [31]:
This mechanism can be proved further by a significant negative correlation 
between dopamine levels and 8-oxo-dG levels in the caudate of AD patients (Figure 2). 
Combined with a significant negative correlation between 8-oxo-dG levels and VMAT2 
density in the same brain area from AD cases (Figure 3), these results are most likely 
owning to Fenton oxidation reactions taking place in the caudate from AD brains, which 
was believed to be a response to dopamine concentration and dopamine compartmen-
talization by VMAT2. As shown in Figure 2, dopamine concentrations in the caudate 
and putamen of disease patients and controls did not significantly differ. However, there 
were trends of decreasing and increasing dopamine levels in the LBD and AD patients, 
especially for the female cohorts.
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PD has been described to be associated with both increased levels of nigral 
iron—a catalytic agent for yielding •OH—and enhanced Mn superoxide dismutase 
activity. As the midbrain levels of reduced glutathione were diminished, there was 
evidence of increased oxidative damage in the midbrain of PD patients, including 
not only lipid peroxidation, protein oxidation, oxidation of DNA, but also catechol 
oxidation in the same brain area of PD cases [11].
As shown in Figure 3, similar changes in VMAT2 density in the caudate and 
putamen are in line with the 8-oxo-dG and dopamine levels of the same cohorts. 
Compared to the controls, lower VMAT2 binding levels were found in the caudate 
from both female and male LBD cases. Diversely, a significant increase in VMAT2 
density in female and male AD patients was observed. We can see significant 
negative correlations between 8-oxo-dG levels and VMAT2 density in the caudate 
(rs = −0.451, p = 0.027) and putamen (rs = −0.516, p = 0.024) of AD patients, 
as well as in the caudate (rs = −0.683, p = 0.042) of PD patients. It might give 
Figure 2. 
Concentration of dopamine in the caudate and putamen from patients with diseases (PD: n = 10, PDD: n = 7, 
DLB: n = 10, and AD: n = 26) and age-matched controls (n = 10). (A) Female and (B) male. The values shown 
are means ± SEM. (C) Concentration of dopamine versus level of 8-oxo-dG in the caudate from diseases 
brains, significant association was observed only in the AD group (p = 0.026); concentration of dopamine 
versus VMAT2 expression in the putamen from diseases brains, significant association was observed only in 
DLB group (p = 0.050). rs, the Spearman’s rank correlation coefficient.
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evidence that the reduction of vesicular storage increased dopamine release and 
then was conductive to produce hydrogen peroxide from MAO-catalyzed dopa-
mine metabolism [32].
To better understand the correlations between oxidative damage and 
dopamine storage abilities, the spatial control of dopamine by VMAT2 and the 
antioxidation role of VMAT2 should be further elucidated. Bearing in mind the 
portrayal of oxidative lesions in the pathogenesis of PD, packing of cytosolic 
dopamine into synaptic vesicles by VMAT2 inhibits its autoxidation and the 
subsequent degeneration of dopaminergic neurons [33]. This theory conforms to 
the negative correlations observed between oxidative damage and VMAT2 den-
sity in striatum of both AD and PD patients. Reduced dopamine levels attenu-
ated its uptake and transport functions by changing dopamine turnover. Thus, 
Figure 3. 
Quantitative autoradiographic analysis of VMAT2 density (fmol/mg) in the caudate and putamen from 
patients with diseases (PD: n = 10, PDD: n = 7, DLB: n = 10, and AD: n = 26) and age-matched controls 
(n = 10). (A) Female and (B) male. The values shown are means ± SEM. Statistical significance between 
two disease groups are indicated with brackets and corresponding p-values. A p value of <0.05 was considered 
significant: * indicates p < 0.05 versus the controls. (C) Density of VMAT2 as concentration of 8-oxo-dG in the 
caudate and putamen from AD brains (p = 0.027 and p = 0.024, respectively) as well as that in the caudate 
from PD brains (p = 0.042). Rs, the Spearman’s rank correlation coefficient.
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VMAT2 expression correlates with the severity of Parkinsonism and cognitive 
impairment in DLB [18, 34]. The inhibition of dopamine metabolism by MAO-B 
attenuates hydrogen peroxide production, as a two-edged sword, it also increases 
the risk of dopamine autoxidation and subsequent augmentation of the cytosolic 
dopamine pool [32].
4.  The interactions between oxidative damage in the striatum, sex, life 
span, and the age of onset of diseases in neurodegenerative patients
Many neurological diseases show significant sex differences in their susceptibil-
ity, severity, and progression [35, 36]. Specifically, a male bias has been found for 
disorders such as PD and attention-deficit hyperactivity disorder (ADHD), both 
of which are associated with abnormal levels of dopamine [37–39]. Considerable 
studies have supported the hypothesis that gonadal sex steroid hormones, especially 
estrogen, act as protectors in females by modulating dopamine release, metabolism, 
and dopamine receptors’ activity. However, there is numerous evidence that genetic 
factors, especially sex-specific genes, influence either healthy or diseased dopamine 
systems [40–42].
As shown in Figure 4, Kendall’s tau_b analysis revealed a significant positive 
correlation between sex and 8-oxo-dG levels in the caudate of PD cases. The result 
indicates that there is a sex difference concerning DNA damage in late-stage PD 
patients. Postmortem brain studies have revealed that the expression of PD-related 
genes in the substantia nigra pars compact (SNc), such as α-synuclein and PINK-1, 
is higher in men than women [43]. Sex-chromosome genes are critically involved, 
particularly the sex-determining region of the Y chromosome (SRY) gene [44]. The 
dopaminergic toxin, 6-hydroxydopamine (6-OHDA), has been described to signifi-
cantly elevate SRY mRNA expression in human male dopamine cells, accompanied 
by an increase in the expression of GADD45γ, a DNA damage-inducible factor gene 
and a known SRY regulator. Interestingly, SRY upregulation initiated by dopamine 
cell damage is a protective response in males; however, the effect diminishes signifi-
cantly with the gradual loss in dopamine cells [19].
DNA damage may be unique in its ability to promote multiple symptoms associ-
ated with old age. Exposure of rodents to ionizing radiation leads to the premature 
Figure 4. 




appearance of numerous histological features of healthy aging—gray hair, kidney 
disease, cataracts, osteoporosis, neuronal atrophy, and muscle atrophy. A classic 
mouse species survive a maximum life span of 2–4 years, whereas humans can 
live up to 122 years [45]. Body mass can account for approximately 60% of the 
mammalian life span variance, while another 40% is attributed to other factors. 
The mitochondrial electron transport chain yields superoxide, a reactive form 
of oxygen, which can damage proteins, lipids, and DNA. Superoxide generates 
immediately into hydrogen peroxide, promoting several forms of oxidative dam-
age. Animals engineered to have reduced rates of oxidative lesions, make efforts to 
exhibit average life spans [46], which provides insights into the significant negative 
correlation between life span and 8-oxo-dG levels in the putamen of healthy aging 
groups (Figure 5). It seems conceivable that transcription-associated DNA damage 
is critically involved in the aging process of mammals.
The reverse is precisely the PDD cases, as shown in Figure 6, there is a signifi-
cantly positive correlation between life span and 8-oxo-dG levels in the caudate of 
PDD patients. The result supporting a role for ROS in regulating the rate of aging 
was characterized as “at best equivocal” in a published comprehensive review 
of aging in the mouse [47], which can be explained as ROS increases life span by 
stimulating protective stress responses [48].
On the other side, quite a few repair enzymes recognize and remove many types 
of DNA damage from the genome, and failure of these mechanisms can lead to the 
accumulation of damage in the neurodegenerative diseases. Failure to repair DNA, 
in reverse, may cause the synthesis of defective proteins, which definitely will repair 
DNA less efficiently [49].
Genome-wide association studies (GWAS) of Huntington’s disease (HD) have 
focused on genes associated with DNA damage repair mechanisms as modifiers 
of age at onset, defining an age-related mechanism shared in other hypotheses 
of neurodegeneration. Many ages at onset in neurodegenerative diseases are 
clarified to be caused by mutations in bona fide DNA repair factors—tyrosyl 
DNA-phosphodiesterase 1 (TDP1), aprataxin (APTX), and polynucleotide kinase/
phosphatase (PNKP) [50]. Getting the picture of DNA repair defects in neuro-
degenerative diseases will shed light on why they affect the age at onset and the 
disease severity in HD.
Figure 5. 
Correlation between life span and 8-oxo-dG concentration in the putamen from the control brains (rs = −0.650, 
p = 0.042). Rs, the Spearman’s rank correlation coefficient.
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An exomic sequencing study in a rare age-related ataxia oculomotor apraxia 
(AOA) identified mutations in the DNA repair scaffold gene XRCC1, the knock-out 
of XRRCC1 resulted in hyper-PARlation, and genetic ablation of PARP1 prevent 
disease onset in an AOA-XRCC1 mouse model [51]. N6-furfuryladenine (N6FFA or 
kinetin)—a natural human metabolite of the DNA repairing ROS damaged adenos-
ine—was protective against neurodegeneration in HD and PD models. The discov-
ery of N6FFA efficacy in HD and PD models indicates a critical signaling pathway 
between DNA damage and mitochondria, where messed branches of this pathway 
may lead to different diseases in the brain, with similarities of late age onset [52]. 
As shown in Figure 7, the significantly positive correlation between age at onset 
and 8-oxo-dG levels in the caudate of the DLB patients, probably indicating that the 
DNA repair pathway, as genetic modifiers, determines the age at onset. 8-oxo-dG 
mainly promotes the transversion from GC to TA, GC to AT, or GC to CG, and this 
Figure 6. 
Correlation between life span and 8-oxo-dG concentration in the caudate from the PDD brains (rs = 0.775, 
p = 0.041). Rs, the Spearman’s rank correlation coefficient.
Figure 7. 
Correlation between age at onset and 8-oxo-dG concentration in the caudate from the DLB brains (rs = 0.800, 
p = 0.010). rs, the Spearman’s rank correlation coefficient.
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is an important mechanism of ROS-induced mutation [53]. The study examined 
the DNA-repair capacities of basal cell carcinoma (BCC) skin cancer patients and 
revealed that the age at the first onset of BCC positively correlated with DNA repair, 
suggesting that the earlier the age of onset, the lower was their DNA repair [54].
5. Conclusion
DNA damage might progressively alter chromatin conformation and, thereby, 
gene expression types with age. Oxidative damage to nucleic acid is altered in 
midbrain structures of PD, DLB, and other neurodegenerative disease patients, 
consequently, inhibiting mitochondrial function. Mitochondrial dysfunction may 
play a vital role in the pathogenesis of neurodegeneration. What is more, there is a 
chicken and egg paradox in the studies trying to correlate neuronal degeneration 
with the signs of DNA damage.
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